Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eayuCrsecrzxgKldwWSz

November 28, 2012
Sign upForwardArchive
News for the PBM Industry

  Featured Story 
  • Generics help offset steep price hikes on brand-name drugs
    Prices for brand-name drugs in the U.S. rose 13.3% from September 2011 to September 2012, and spending on specialty drugs has climbed 22.6% over the first three quarters of 2011, according to a study by pharmacy benefit manager Express Scripts. However, a generic drug utilization rate close to 80% helped curb overall drug spending, the study found. Reuters (11/28) LinkedInFacebookTwitterEmail this Story
 Registration is now open for PCMA's Managed Markets Educational Forum!
Whether you are a seasoned managed markets executive or someone who supports the team, PCMA's Managed Markets Educational Forum will provide valuable education on fundamental, as well as complex and strategic issues relevant to professionals of all levels within pharma managed markets or market access divisions. Visit PCMA's website to learn more about our 2013 events!
 

  Legislative & Regulatory News 
  PBM Industry News 
  • Expert: Proposed EHB rule offers formulary flexibility
    Proposed HHS rules would require that insurance plans sold on exchanges cover the greater of either one drug in each therapeutic class or the same number of drugs in each class as covered in a state's benchmark plan. The requirement applies to the number of drugs covered, leaving open the option of including different drugs on plan formularies, writes industry expert Adam Fein. Drug Channels (11/27) LinkedInFacebookTwitterEmail this Story
  Drug Industry Spotlight 
  • Indian patent board upholds ruling against AstraZeneca
    India's Intellectual Property Appellate Board dismissed AstraZeneca's challenge to a ruling that negated the drugmaker's patent on a quinazoline derivative. The ruling is similar to other recent rulings in the country voiding drugmaker patents. Reuters (11/28) LinkedInFacebookTwitterEmail this Story
  • Wockhardt gets 3 generic-drug approvals from FDA
    The FDA has granted Wockhardt approval for its generic version of Bristol-Myers Squibb and Sanofi's anticoagulant Plavix. The company has also received approvals for its generic copies of GlaxoSmithKline's antidepressant drug Wellbutrin SR and Novartis' Parkinson's disease drug Stalevo. Drug Store News (11/27) LinkedInFacebookTwitterEmail this Story
  SmartQuote 
The foolish man seeks happiness in the distance; the wise grows it under his feet."
--James Oppenheim,
American poet, novelist and editor


LinkedInFacebookTwitter

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

 
Contact PCMA
Charles Cote
Assistant Vice President, Strategic Communications
(202) 207-3610

Twitter  Follow PCMA on Twitter
 
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

 
 Recent PCMA SmartBrief Issues:   Lead Editor:  Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information